CND Life Sciences

📍 Scottsdale, United States🗓 Founded 2017👥 61 employees💰 Last funded Jan 2021
Medical and Diagnostic Laboratories🌐 cndlifesciences.com
Website LinkedIn
CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, AZ, CND launched the Syn-One Test® as the first commercially available test to detect, visualize, and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid in the confirmation of a synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF). Through analysis of three small in-office skin biopsies provided by a referring physician, CND offers a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases. The company has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Spain
1
United States
1
Frequently asked questions
Who invested in CND Life Sciences?
CND Life Sciences has 2 investors on record on gritt.io, 2 mid-stage.
When did CND Life Sciences last raise funding?
The most recent investment in CND Life Sciences recorded on gritt.io was in January 2021.
When was CND Life Sciences founded?
CND Life Sciences was founded in 2017.
What industry is CND Life Sciences in?
CND Life Sciences operates in Medical and Diagnostic Laboratories. Find similar Medical and Diagnostic Laboratories investors on gritt.io.
Where is CND Life Sciences based?
CND Life Sciences is headquartered in Scottsdale, United States.